Moxidectin and Ivermectin Inhibit SARS-CoV-2 Replication in Vero E6 Cells but Not in Human Primary Bronchial Epithelial Cells
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Antiviral therapies are urgently needed to treat and limit the development of severe COVID-19 disease. Ivermectin, a broad-spectrum anti-parasitic agent, has been shown to have anti-SARS-CoV-2 activity in Vero cells at a concentration of 5 μM.
Article activity feed
-
-
-
SciScore for 10.1101/2021.05.17.444467: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: The medical ethics committee of the University Medical Center Groningen approved the study (METC 2019/338), and all subjects gave their written informed consent.
Consent: The medical ethics committee of the University Medical Center Groningen approved the study (METC 2019/338), and all subjects gave their written informed consent.Sex as a biological variable The donors were 3 male and 2 female non-smoking healthy control volunteers, with a normal lung function (FEV/FVC > 70%, FEV1 > 90 Randomization not detected. Blinding not detected. Power Analysis not detected. Cell Line Authentication Contamination: All cells were mycoplasma negative and maintained at 37 °C under 5% CO2. Table 2: Resources
… SciScore for 10.1101/2021.05.17.444467: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: The medical ethics committee of the University Medical Center Groningen approved the study (METC 2019/338), and all subjects gave their written informed consent.
Consent: The medical ethics committee of the University Medical Center Groningen approved the study (METC 2019/338), and all subjects gave their written informed consent.Sex as a biological variable The donors were 3 male and 2 female non-smoking healthy control volunteers, with a normal lung function (FEV/FVC > 70%, FEV1 > 90 Randomization not detected. Blinding not detected. Power Analysis not detected. Cell Line Authentication Contamination: All cells were mycoplasma negative and maintained at 37 °C under 5% CO2. Table 2: Resources
Experimental Models: Cell Lines Sentences Resources Cell culture: The African green monkey Vero E6 cell line (ATCC CRL-1586), kindly provided by Gorben Pijlman (Wageningen University, Wageningen, the Netherlands) was maintained in Dulbecco’s minimal essential medium (DMEM) (Gibco, Paiskey, UK), high glucose supplemented with 10% fetal bovine serum (FBS) (Lonza, Basel, Switzerland), penicillin (100 U/mL), and streptomycin (100 U/mL) (Gibco, Paiskey, UK). Vero E6suggested: NoneCalu-3 cells were seeded at a density of 2 ×105 cells/well in 24-well plates. Calu-3suggested: NoneSoftware and Algorithms Sentences Resources All data were analyzed in GraphPad Prism software (La Jolla, CA, USA). GraphPad Prismsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Many of these trials have serious limitations such as small sample size, lack of binding, lack of pre-registration for some trials and therefore carries a risk of bias (Ahmed et al., 2021; Chaccour et al., 2021; Chowdhury et al., 2020; Elgazzar et al., 2020; Hashim et al., 2020; Okumuş et al., 2021; Podder et al., 2020; Rajter et al., 2021; Soto-Becerra et al., 2020; WHO, 2021b). Apart from the problem of bias, only five trials (April 29, 2021), directly compared ivermectin with standard of care and reported clinically crucial outcomes such as mortality (Gonzalez et al., 2021; Lopez-Medina et al., 2021; Mohan et al., 2021; Niaee et al., 2020; Ravikirti. et al., 2021). The WHO recently stated: “the current evidence of effect of ivermectin on mortality, mechanical ventilation, hospital admission and duration of hospitalization remains uncertain” (WHO, 2021b). Yet, many clinical trials are still ongoing. The observed lack of antiviral activity of ivermectin in the biologically relevant PBECs model reported here together with the poor pharmacological properties of ivermectin (Momekov and Momekova, 2020; Pena-Silva et al., 2020; Schmith et al., 2020) do not forecast a success of the ongoing clinical trials for its usage in COVID-19 patients. SARS-CoV-2 can also infect several economically important livestock such as cats, dogs, minks, lions and tigers (Lam et al., 2020; McAloose et al., 2020; Oreshkova et al., 2020; Patterson et al., 2020; Sharun et al., 2020; Shi et al., 2020). I...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-